Hall E D
CNS Diseases Research, Upjohn Company, Kalamazoo, Michigan.
J Neurosurg. 1988 Mar;68(3):462-5. doi: 10.3171/jns.1988.68.3.0462.
The ability of a single intravenous dose of the 21-aminosteroid U74006F to affect the development of posttraumatic spinal cord ischemia was examined in pentobarbital-anesthetized cats. After surgical preparation, each animal received a 300 gm-cm contusion injury to the exposed L-3 vertebral segment, followed by a single bolus injection of vehicle or U74006F (3 or 10 mg/kg) at 30 minutes postinjury. Spinal cord white matter blood flow (SCBF) was measured by hydrogen clearance in the dorsolateral funiculus in the center of the injured segment before and at various times up to 4 hours after injury. In vehicle-treated cats, there was a progressive decline in SCBF over the course of the experiment. By 4 hours postinjury, SCBF had decreased from a preinjury value of 15.9 +/- 2.4 ml/100 gm/min (mean +/- standard error of the mean) to 5.8 +/- 0.8 ml/100 gm/min, representing a decline of 63.5%. In contrast, the SCBF measured 4 hours postinjury in cats that were treated with a single 10-mg/kg dose of U74006F was 13.6 +/- 1.7 ml/100 gm/min (p less than 0.001 vs. vehicle). Animals that received a 3-mg/kg intravenous dose of U74006F displayed a drop in SCBF equal to that of vehicle-treated cats. However, when a 3-mg/kg dose of U74006F was given to four vehicle-treated cats at the end of the experiment, a partial reversal of ischemia was recorded. Blood flow increased within 30 minutes from a mean of 4.5 +/- 0.8 to 7.4 +/- 1.0 ml/100 gm/min or an increase of 64.4% (p less than 0.05). This rather surprising effect of U74006F in reversing posttraumatic ischemia once it has developed significantly is not shared by a 30-mg/kg intravenous dose of methylprednisolone sodium succinate (MP), although MP has previously been shown to attenuate the posttraumatic drop in SCBF when given before the SCBF drop occurs. The mechanism of action of U74006F in antagonizing posttraumatic ischemia development is believed to involve the ability of the compound to inhibit iron-dependent lipid peroxidation in central nervous system tissue.
在戊巴比妥麻醉的猫身上,研究了单次静脉注射21-氨基类固醇U74006F对创伤后脊髓缺血发展的影响。手术准备后,每只动物的L-3椎体节段暴露在外,受到300克厘米的挫伤,然后在受伤后30分钟单次推注赋形剂或U74006F(3或10毫克/千克)。在受伤前以及受伤后长达4小时的不同时间,通过氢清除法测量损伤节段中央背外侧索的脊髓白质血流量(SCBF)。在接受赋形剂治疗的猫中,实验过程中SCBF逐渐下降。受伤后4小时,SCBF从受伤前的15.9±2.4毫升/100克/分钟(平均值±平均标准误差)降至5.8±0.8毫升/100克/分钟,下降了63.5%。相比之下,单次静脉注射10毫克/千克剂量U74006F的猫在受伤后4小时测量的SCBF为13.6±1.7毫升/100克/分钟(与赋形剂组相比,P<0.001)。接受3毫克/千克静脉注射剂量U74006F的动物,其SCBF下降程度与接受赋形剂治疗的猫相同。然而,在实验结束时,给4只接受赋形剂治疗的猫静脉注射3毫克/千克剂量的U74006F后,记录到缺血有部分逆转。血流量在30分钟内从平均4.5±0.8增加到7.4±1.0毫升/100克/分钟,即增加了64.4%(P<0.05)。尽管甲基强的松龙琥珀酸钠(MP)在SCBF下降之前给药时,先前已显示可减轻创伤后SCBF的下降,但30毫克/千克静脉注射剂量的MP并没有U74006F这种在创伤后缺血显著发展后逆转缺血的惊人效果。U74006F拮抗创伤后缺血发展的作用机制被认为与该化合物抑制中枢神经系统组织中铁依赖性脂质过氧化的能力有关。